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Aggressive B-cell lymphoma (BCL) comprises a heterogeneous group of malignancies, including diﬀuse large B-cell lymphoma
(DLBCL), Burkitt lymphoma, and mantle cell lymphoma (MCL). DLBCL, with its 3 subtypes, is the most common type of lym-
phoma. Advances in chemoimmunotherapy have substantially improved disease control. However, depending on the subtype,
patients with DLBCL still exhibit substantially diﬀerent survival rates. In MCL, a mature B-cell lymphoma, the addition of rituxi-
mabtoconventionalchemotherapyregimenshasincreasedresponserates,butnotsurvival.Burkittlymphoma,themostaggressive
BCL, is characterized by a high proliferative index and requires more intensive chemotherapy regimens than DLBCL. Hence, there
is a need for more eﬀective therapies for all three diseases. Increased understanding of the molecular features of aggressive BCL has
led to the development of a range of novel therapies, many of which target the tumor in a tailored manner and are summarized in
this paper.
1.Introduction
Many variations of aggressive B-cell lymphoma (BCL) exist,
eachwithdistinctmolecular,biological,andcytogeneticcha-
racteristics [1]. Examples include diﬀuse large B-cell lym-
phoma (DLBCL), Burkitt lymphoma, and mantle cell lym-
phoma (MCL). Malignant lymphomas can arise at multiple
stages of normal B-cell development, with the germinal cen-
terservingastheprobableoriginofmanytypesoflymphoma
[2]. In the germinal-center reaction, mature B cells are acti-
vated by antigen, in conjunction with signals from T cells.
During this process, B-cell DNA is modiﬁed, which results
in an altered B-cell receptor. These genetic modiﬁcations
are prerequisite to a normal immune response but are also
the source of genetic defects that result in accumulated
molecular alterations during the lymphomagenesis process
[3–5].
DLBCL is the most common lymphoid malignancy,
accounting for approximately 25 to 30% of all adult lym-
phomas in the western world [6]. Chemoimmunotherapy
with rituximab plus anthracycline-based combination regi-
mens has substantially improved long-term disease control,
with more than 50% of patients still in remission 5 years
after treatment [7–10]. There are 3 histologically indistin-
guishablemolecularsubtypesofDLBCL:theactivatedB-cell-
like (ABC) subtype, the germinal-center B-cell-like (GCB)
subtype, and primary mediastinal BCL (PMBL) [11–13].
Thesesubtypesdiﬀerintermsofgeneexpression[13,14]and
are believed to originate in B cells at diﬀerent stages of diﬀe-
rentiation [15]. In addition, the process of malignant trans-
formation diﬀers for each subtype, resulting in distinctive
patterns of genetic abnormality [11, 15]. Clinical presenta-
tion and responsiveness to targeted therapies also vary across
the subtypes.
Gene expression in GCB lymphomas is characteristic for
germinal-center B cells [11, 15, 16], with, for example, dele-
tionofthetumorsuppressorgenePTEN [17],andp53muta-
tions [18] being speciﬁc to GCB lymphomas. Genetic abnor-
malities that are characteristic for ABC DLBCL include,
for example, deletion of the INK4α/ARF tumor suppressor
locus on chromosome 9 and ampliﬁcation of a 9-Mb region
on chromosome 19 [19]. Loss of these tumor suppressors
impedes the action of chemotherapy and may contribute
to the poor prognosis associated with this subtype. PMBL,2 Advances in Hematology
although not easily diﬀerentiated clinically from other lym-
phoma subtypes, is readily distinguishable by gene-expres-
sion proﬁling [12, 13]s u c ha sd e l e t i o no fSOCS1, a suppres-
sor of JAK signaling [20–22].
Burkitt lymphoma, an aggressive BCL characterized by
a high degree of proliferation of the malignant cells and
deregulation of the MYC gene, relies on morphologic ﬁnd-
ings, immunophenotyping results, and cytogenetic features
for diagnosis [2]. However, DLBCL and Burkitt lymphoma
can have overlapping morphologic and immunophenotypic
features,andthecharacteristict(8;14)translocationfoundin
Burkittlymphomaalsooccursin≤15%ofDLBCLcases[23].
While the regimen of rituximab, cyclophosphamide, hydrox-
ydaunorubicin, vincristine, and prednisone (R-CHOP) is
typically used as a ﬁrst-line treatment for DLBCL, Burkitt
lymphoma requires more intensive chemotherapy regimens
[24].
MCL, a mature B-cell lymphoma, is almost invariably
associated with the t(11;14) translocation with overexpres-
sion of cyclin D1 [25]. Several morphologic variants exist,
some of which are predictive of a poorer prognosis [26].
Deletions of the INK4α/ARF locus on chromosome 9p21
[27] and mutations of p53 in 17p13, for instance, are also
associated with a more aggressive histology [27–29].
Signiﬁcant progress has been made in the management
of patients with aggressive DLBCL. Addition of rituximab to
the CHOP regimen (R-CHOP) [30] has resulted in fewer pa-
tients with disease progression. However, recent trial results
have provided no evidence to indicate that rituximab com-
bined with CHOP given every 14 days (R-CHOP14) impro-
ves overall survival (OS) or progression-free survival (PFS)
comparedwiththestandardregimenofR-CHOPgivenevery
21 days (R-CHOP21) in newly diagnosed DLBCL [31].
Consequently, a substantial unmet need still exists. De-
pending on the DLBCL subtype, patients experience sig-
niﬁcantly diﬀerent survival rates following chemotherapy,
with the ABC subtype in particular being associated with a
poorer outcome [11, 19, 32]. Recurrent disease, especially
after rituximab exposure, is also a concern, and patients with
early relapse after rituximab-containing ﬁrst-line therapy
have been shown to have a poor prognosis [33]. In MCL, the
addition of rituximab to conventional chemotherapy regi-
mens has increased overall response rates (ORRs), but not
OS compared with chemotherapy alone [34].
As we further our understanding of the molecular char-
acteristicsofaggressiveBCL,wehopeitwillleadtothedesign
of therapies that target the tumor and its microenvironment
more directly and more eﬀectively.
2. Cytotoxic Therapies
Several new cytotoxic agents are being investigated for the
treatment of aggressive lymphomas (Table 1). Bendamus-
tine has shown single-agent and combination activity in
indolent lymphomas [35–37]. Although approved for this
indication in some countries, evidence supporting its use in
treating aggressive lymphomas has been limited. Recently,
a feasibility and pharmacokinetic study of bendamustine
in combination with rituximab in relapsed or refractory
(R/R) aggressive B-cell non-Hodgkin lymphoma (NHL)
conﬁrmed that bendamustine 120mg/m2 plus rituximab
375mg/m2 was feasible and well tolerated and showed pro-
mising eﬃcacy [38]. A subsequent phase II study of ben-
damustine as monotherapy showed a 100% ORR and a 73%
complete response (CR) in R/R MCL patients [39]. Preli-
minary data of another study of bendamustine in combi-
nation with rituximab in elderly patients with R/R DLBCL
demonstrated an ORR of 52% [40]. A phase III study of
this combination showed better eﬃcacy than a ﬂudarabine-
rituximab combination in patients with relapsed follicular,
other indolent NHLs and MCL [41]. In another phase III
study in previously untreated indolent BCL and MCL pa-
tients, the bendamustine-rituximab regimen was superior to
R-CHOPintermsofCRandPFS[42].Retrospectiveanalyses
of clinical use in Italy [43]a n dS p a i n[ 44] have indicated
that treatment with bendamustine alone, or in combination
with rituximab, is eﬃcacious and has an acceptable safety
proﬁle in heavily pretreated NHL and chronic lymphocytic
leukemia (CLL) patients. The most common adverse events
associated with bendamustine were hematologic or gastroin-
testinal in nature and mild to moderate in intensity.
The activity proﬁle of the gemcitabine-oxaliplatin
(GEMOX) combination makes it an attractive regimen for
use as salvage therapy for several types of lymphoma.
Phase II studies have demonstrated signiﬁcant activity of
GEMOX in combination with rituximab (GEMOX-R) in
R/R DLBCL [45]a n dM C L[ 46]. The major toxicities obser-
ved with this regimen were grade 3 or 4 neutropenia and
thrombocytopenia. Promising activity with acceptable tox-
icity has been shown for GEMOX-R in patients with R/R
B-cell NHL who are ineligible for high-dose therapy [47]
or subsequent transplant [48]. A phase III trial of the novel
aza-anthracenedione pixantrone dimaleate [49]w a sp r o m p -
ted by the absence of reliable durable eﬃcacy in patients
with aggressive NHL who have relapsed following multiple
lines of therapy. This trial showed superior eﬃcacy compa-
red with a number of alternative third-line single-agent
therapies. Neutropenia and leukopenia were the most com-
mon grade 3 or 4 adverse events. A second phase III trial,
comparing pixantrone-rituximab with gemcitabine-rituxi-
mab in patients with R/R DLBCL that are not eligible for
stem cell transplantation (SCT), is currently recruiting
(NCT01321541). A liposomal formulation of vincristine has
also shown activity in patients with aggressive NHL that
have relapsed after second-line therapy [50]; grade 3 or 4
neurotoxicity occurred in 32% of patients.
Other novel agents target mitotic spindle proteins; Eg5,
for example, has emerged as a unique mitotic spindle target
[51]. SB-743921 is a novel kinesin spindle protein inhibitor
that has shown signiﬁcant activity in both in vivo and in vitro
models of aggressive DLBCL. In a phase I/II dose-ﬁnding
s t u d y ,a c t i v i t yw a so b s e r v e di nh e a v i l yp r e t r e a t e dN H La n d
Hodgkin lymphoma (HL) patients, with neutropenia (47%)
reported as the most frequent grade 3 or 4 toxicity [52].
Clofarabine is a second-generation purine analog appro-
ved by the United States Food and Drug AdministrationAdvances in Hematology 3
Table 1: Cytotoxic therapies in clinical development for the treatment of aggressive NHL. [B: bendamustine; CLL: chronic lymphocytic
leukemia; CR: complete response; CRu: unconﬁrmed CR; DLBCL: diﬀuse large B-cell lymphoma; EFS: event-free survival; F: ﬂudarabine;
HL: Hodgkin lymphoma; MCL: mantle cell lymphoma; MOA: mechanism of action; mOS: median overall survival; mPFS: median
progression-free survival; NHL: non-Hodgkin lymphoma; ORR: overall response rate; OS: overall survival; P: pixantrone; PFS: progression-
free survival; PR: partial response; R: rituximab; R-CHOP: cyclophosphamide, doxorubicin, vincristine, prednisolone plus rituximab; R/R:
relapsed or refractory; SD: stable disease.]
Drug MOA (target) Eligibility
(and design) Phase Randomized Results
Bendamustine [46] Alkylating agent R/R NHL/CLL Registry No ORR: 84.6% in MCL
Bendamustine [45] Alkylating agent R/R Lymphoma (±R) Retrospective
analysis
No
MCL: ORR: 67%; 1-year
OS: 68%; 1-year PFS: 15%
DLBCL: ORR: 31%; 1-year
OS: 27%; 1-year PFS: 10%
Bendamustine [42] Alkylating agent R/R DLBCL (+R) No ORR: 51.6%
Bendamustine [40] Alkylating agent R/R aggressive NHL I No B9 0m g / m 2: ORR: 33%;
B 120mg/m2: ORR: 100%
Bendamustine [41] Alkylating agent R/R MCL/NHL II No ORR: 100% in MCL
Bendamustine [44] Alkylating agent
Previously untreated
follicular + indolent +
MCL (with R versus
R-CHOP)
III Yes
BR versus R-CHOP: CR:
40.1% versus 30.8% (P =
.0323); PFS: 54.8 months
versus 34.8 months (P =
.0002); OS: no diﬀerence
Bendamustine [43] Alkylating agent
Follicular + indolent
+M C Lw i t hRv e r s u s
FR
III Yes
BR versus FR: CR: 83.5%
versus 52.5% (P<. 0001);
PFS: 30 months versus 11
months (P<. 0001); OS: no
diﬀerence
Pixantrone [49] Aza-
anthracenedione
R/R aggressive NHL
(versus other single
agents)
III Yes
P versus comparator: ORR:
37% versus 14%; CR/CRu:
20% versus 6%; PFS: 4.7
versus 2.6 months; mPFS
(P = .007); mOS: 8.1 versus
6.9 months (HR = 0.88, P =
.554)
SB-743921 [51] Kinesin spindle
protein inhibitor R/R HL or NHL I/II dose-ﬁnding
study
No
4P R s :3i nH L ,1i nm a r -
ginal-zone NHL; 1 durable
SD (>17 months) in DLB-
CL
Gemcitabine/oxaliplatin [45] Chemotherapy R/R DLBCL with
rituximab II No
ORR: 43%; CR: 34%; 12-
month PFS rate: 29%; 12-
month OS rate: 41%
Gemcitabine/oxaliplatin [46] Chemotherapy R/R MCL with
rituximab
No
CR/CRu: 77%; 2-year PFS
rate: 41%; 2-year OS rate:
58%
Gemcitabine/oxaliplatin [47] Chemotherapy R/R B-cell NHL with
rituximab II No
ORR: 83%; CR/CRu: 50%;
2-year EFS: 42%; 2-year OS:
66%
Gemcitabine/oxaliplatin [48] Chemotherapy
R/R B-cell NHL
(transplant ineligible)
with R
No
GemOx: ORR: 57%; CR:
30% R-GemOx: ORR: 78%;
CR: 50%
Liposomal vincristine [50] Chemotherapy R/R NHL II No ORR: 25%; CR/CRu: 5%
(FDA) for intravenous use in R/R pediatric acute lym-
phoblastic leukemia (ALL). Purine analogs demonstrate sig-
niﬁcant clinical activity in NHL, with a phase I preliminary
evaluation of an oral formulation of clofarabine in relapsed
or refractory NHL reporting an ORR of 35%, with no grade
3 or 4 nonhematologic toxicities [53].
3.Antibodies
3.1.Anti-CD20MonoclonalAntibodies(mAbs)(Table 2). The
chimeric anti-CD20 mAb rituximab improved therapeutic
outcomes considerably for patients with B-cell malignan-
cies, particularly when combined with chemotherapy [54].4 Advances in Hematology
Table 2: Therapeutic antibodies in clinical development for the treatment of aggressive NHL. [CR: complete response; CRu: unconﬁrmed
CR; DLBCL: diﬀuse large B-cell lymphoma; EFS: event-free survival; EOTR: extent of tumor resection; FL: follicular lymphoma; HL:
Hodgkin lymphoma; mAb: monoclonal antibody; MCL: mantle cell lymphoma; mDR: median duration of response; MOA: mechanism of
action; mPFS: median progression-free survival; MZL: marginal zone B-cell lymphoma; NHL: non-Hodgkin lymphoma; ORR: overall
response rate; OS: overall survival; PFS: progression-free survival; PR: partial response; R-CHOP: cyclophosphamide, doxorubicin,
vincristine, prednisolone plus rituximab; R: rituximab; R/R: relapsed or refractory; RR: response rate.]
Drug MOA (target) Eligibility
(and design)
Phase Randomized Results
Ofatumumab [60] Anti-CD20 mAb R/R DLBCL II No ORR: 11%; CR: 4%; mDR: 6.9
months; mPFS: 2.5 months
GA101 [67] Anti-CD20 mAb R/R DLBCL and
MCL
II Yes EOTR:All:28%;DLBCL:29%;
MCL: 27%
Veltuzumab [56] Anti-CD20 mAb R/R NHL I/II No
ORR: DLBCL: 43%; MZL:
83%, including CR/CRu: 33%
ORR: FL: 44%, including
CR/CRu: 27%
Epratuzumab [69] Anti-CD22 mAb R/R NHL (with
rituximab)
II No ORR: 47%; DLBCL: CR: 33%
Epratuzumab [70] Anti-CD22 mAb
Previously
untreated DLBCL
(with R-CHOP)
II No
ORR: 95%; CR/CRu: 73%; 1-
year EFS rate: 80%; 1-year PFS
rate: 82%; 1-year OS rate: 88%
Milatuzumab [57] Anti-CD74 mAb R/R NHL (with
veltuzumab)
I/II Dose-ﬁnding PR: 1/3 in Cohort 1 (8mg/kg);
2/3 in Cohort 2 (16mg/kg)
Dacetuzumab [77] Anti-CD40 mAb
R/R DLBCL (with
rituximab and
gemcitabine)
Ib Dose-ﬁnding ORR: 54%
Lucatumumab [74] Anti-CD40 mAb R/R HL or NHL Ia/II Dose-ﬁnding
RR: R refractory: 40%; ORR:
DLBCL: 11% (phase Ia); ORR:
DLBCL: 15% (phase II)
Blinatumomab
(MT103) [83]
Single-chain
bispeciﬁc
anti-CD19 and
CD3 mAb
construct
R/R NHL I Dose-ﬁnding FL: 11/21 responses;
MCL: 3/21 responses
However, resistance and reduced response to retreatment
led to the development of second-generation humanized (or
primarilyhuman)mAbs,whichhavegreatercytotoxicityand
stronger direct eﬀects on B cells.
Veltuzumab is a humanized CD20 mAb with comple-
mentarity-determining regions diﬀering from rituximab by
only 1 amino acid, a characteristic believed to account for
the markedly reduced oﬀ-rates demonstrated by veltuzumab
compared with rituximab [55]. A major response was de-
monstrated in a phase I/II dose-escalation trial in patients
with R/R NHL, with no evidence of immunogenicity [56].
B-cell depletion was observed from ﬁrst infusion, even at the
lowest dose of 80mg/m2. Adverse events were transient, mild
to moderate, and occurred mostly at ﬁrst infusion, a notable
ﬁnding given the short infusion times. A phase I study with
veltuzumab in combination with the anti-CD74 antibody
milatuzumab in patients with R/R NHL is ongoing [57].
The fully human CD20 mAb, ofatumumab, has been
FDA-approved for the treatment of ﬂudarabine- and alem-
tuzumab-refractory CLL [58] and is currently being eval-
uated in NHL. Ofatumumab induces B-cell depletion via
mechanisms similar to rituximab, but with substantially
more complement-dependent cytotoxicity. Recent in vivo
data suggest ofatumumab may be more potent than rit-
uximab in both rituximab-sensitive and rituximab-resistant
models and may potentiate the antitumor activity of chemo-
therapy agents commonly used in the treatment of B-cell
NHL [59]. Initial results from a phase II study in relapsed or
progressive DLBCL showed that single-agent ofatumumab is
well-tolerated with evidence of eﬃcacy [60]. In this patient
population, response to the last systemic treatment appeared
to inﬂuence response to ofatumumab; a subsequent study of
ofatumumab in combination with ifosfamide, carboplatin,
etoposide (ICE) or dexamethasone, Ara-C, and cisplatin
(DHAP) chemotherapy regimens (NCT00823719) is ongo-
ing.
GA101 is a novel humanized CD20 mAb that binds
CD20 in a manner completely diﬀerent to that of rituximab
and ofatumumab [61]. In preclinical studies it has demon-
strated superior eﬃcacy compared with both agents [62, 63],
and an initial phase I trial with dosing every three weeks
demonstrated promising activity with no dose-limiting toxi-
city(DLT)[64].Aseconddose-ﬁndingstudyinpatientswith
R/R NHL (n = 22; ORR: 25% at 3 months) [65]h a sb e e n
followed by a phase II study in heavily pretreated patients
with R/R DLBCL and MCL. Treatment was well tolerated,Advances in Hematology 5
and promising evidence of eﬃcacy was shown [66]. Recent
in vivo studies have shown enhanced inhibition of tumor
growth for GA101 in combination with bendamustine, ﬂu-
darabine, and the B-cell lymphoma 2 (Bcl-2) family inhibi-
tors ABT-737 and ABT-263 [67].
3.2. Novel Targeted mAbs (Table 2). The humanized mAb,
epratuzumab, targets CD22 which is a B-cell marker thought
to play a role in B-cell activation, cell-surface receptor
circulation, and modulation of antigen-receptor signaling
[68]. In a phase II trial in patients with R/R NHL, the com-
bination of epratuzumab and rituximab resulted in con-
siderable ORRs in both follicular lymphoma and DLBCL
[69]. In a subsequent phase II study, in which epratuzumab
was added to R-CHOP as ﬁrst-line therapy for DLBCL, an
ORR of 95% was reported. Substantial responses were doc-
umented even when patients were separated into low- and
high-risk international prognostic index (IPI) groups [70].
Positron emission tomography (PET) scan data conﬁrmed
a functional CR rate of 87% in this study, with attainment
of PET negativity by completion of therapy being associated
with a good outcome [71].
Milatuzumab is a humanized anti-CD74 mAb in clinical
evaluation for the treatment of multiple myeloma (MM),
CLL,andNHL.Inpreclinicaltrials,milatuzumabmonother-
apy has demonstrated therapeutic activity against various
B-cell malignancies, while the addition of milatuzumab to
numerous agents including rituximab and ﬂudarabine en-
hanced the therapeutic eﬃcacy in a variety of B-cell malig-
nancy cell lines [72]. As milatuzumab combined with rit-
uximab was shown to cause MCL cell death [73], further
evaluation of this combination in MCL is warranted. A dose-
escalation study of a milatuzumab-veltuzumab regimen in
R/R NHL is ongoing [57].
Lucatumumab (HCD122), a mAb that is a pure antago-
nist of the CD40 transmembrane receptor, has been evalu-
ated clinically in CLL and MM and is currently under evalu-
ation in a variety of lymphomas, including DLBCL and MCL
[74]. Initial eﬃcacy has been shown in an ongoing phase
Ia/II trial in patients who had progressed after multiple prior
therapies, with DLTs limited to clinically asymptomatic and
reversiblegrade3or4elevationsofamylaseand/orlipaseand
grade 3 or 4 elevations of alanine aminotransferase (ALT)
and/or aspartate aminotransferase (AST).
The humanized anti-CD40 mAb, dacetuzumab (SGN-
40), has demonstrated antiproliferative and apoptotic activ-
ity against a panel of high-grade BCL cell lines [75]. Dace-
tuzumab was shown to enhance the antitumor activity of
rituximabinNHLcelllinesandxenograftmodels,suggesting
that antibody-mediated signaling through both CD20 and
CD40 may be an eﬀective strategy in the treatment of NHL
[76].Dacetuzumabincombinationwithrituximabandgem-
citabine for the treatment of NHL is currently being evalu-
ated in a phase Ib study [77].
Small modular immunopharmaceuticals (SMIPs) are
single-polypeptide chains consisting of a single-chain Fv
linked to human IgG hinge, CH2, and CH3 domains [78].
TRU-016, a novel humanized anti-CD37 SMIP protein, has
demonstrated single-agent activity as well as synergy with
bendamustine, rituximab, rapamycin, and temsirolimus and
an additive beneﬁt with doxorubicin [79–81]. TRU-016 is
currently being evaluated in a phase I study in relapsed NHL
and CLL (NCT00614042).
3.3. Bispeciﬁc Antibodies (BsAbs). New mAbs are being tested
in combination with rituximab, including BsAbs that target
CD20 and CD22 simultaneously [82]. HB22.7 is an anti-
CD22 mAb that speciﬁcally blocks the interaction of CD22
with its ligand, has direct cytotoxic eﬀects, and initiates
CD22-mediated signal transduction. The cell binding, sig-
naling patterns, and lymphomacidal activity of a BsAb
(Bs20x22) combining rituximab and HB22.7 have been eval-
uated using a xenograft model of human NHL. Eﬃcacy was
demonstrated by in vitro cytotoxicity and apoptosis assays,
p38 activation, and xenograft models. Bs20x22 appeared to
be more eﬃcacious than the combination of rituximab and
HB22.7 and eliminated the need for sequential administra-
tion of 2 separate mAbs.
The recent creation of an anti-CD20/human leukocyte
antigen(HLA)-DR-interferon-(IFN-)α2β BsAbimmunocy-
tokine (designated 20-C2-2β)i se x p e c t e dt oh a v eg r e a t e rin
vivo potency than IFN-α due to improved pharmacokinetics
and targeting speciﬁcity and may potentially be useful in a
variety of hematopoietic tumors that express either CD20 or
HLA-DR [83].
Bispeciﬁc T-cell engager molecules (BiTEs) are antibod-
ies that target both an antigen on malignant cells and CD3
on the surface of T cells [84]. In a phase I trial in relapsed
NHL, the anti-CD19/CD3 BiTE antibody, blinatumomab,
produced multiple responses in 52 patients. Implementation
of a double-step dose-escalation procedure avoided treat-
ment discontinuations due to CNS events [85].
Recently, preclinical data have been presented for a num-
berofotheragents,includinganti-HLA-DRhumanizedmAb
IMMU-114[86],anti-CD47antibody[87],anti-CD137anti-
body [88], and the anti-CD19 mAb XmAb5574 [89].
3.4. Antibody-Drug Conjugates (ADCs) (Table 3). ADCs are
mAbs attached to cytotoxic drugs via chemical linkers [90].
Inotuzumabozogamicin (CMC544) iscomposed of theanti-
CD22 antibody inotuzumab and calicheamicin, a cytotoxic
agentderivedfromthebacteriaMicromonosporaechinospora,
which acts by cleaving DNA [91]. A phase I trial with 48
patients with R/R lymphoma showed ORRs of 69% and
33% for follicular lymphoma and DLBCL, respectively [92].
Inotuzumab ozogamicin was well tolerated; the most fre-
quent adverse event was thrombocytopenia, which occurred
at grade 3 or 4 in 57% of patients. In a phase I/II trial
where inotuzumab was combined with rituximab in patients
with relapsed follicular lymphoma or DLBCL, the response
rates and 6-month PFS were 88% and 100% for follicular
lymphoma and 71% and 66% for DLBCL, respectively [93].
Recently, preliminary results from a trial of inotuzumab
plus rituximab in relapsed DLBCL patients followed by SCT
were reported [94]. A best ORR of 21% was observed,
with no new safety concerns. The inotuzumab-rituximab
combination was also used in a study in Japanese patients
with R/R B-cell NHL, resulting in an ORR of 80%; adverse6 Advances in Hematology
Table 3: Antibody-drug conjugates and radiolabeled antibodies in clinical development for the treatment of aggressive NHL. [CR: complete
response; CRu: unconﬁrmed CR; DLBCL: diﬀuse large B-cell lymphoma; HDT-ASCT: high-dose therapy/autologous stem cell transplanta-
tion; mAb: monoclonal antibody; MOA: mechanism of action; mPFS: median progression-free survival; NHL: non-Hodgkin lymphoma;
ORR: overall response rate; OS: overall survival; PFS: progression-free survival; R: rituximab; R-CHOP: cyclophosphamide, doxorubicin,
vincristine, prednisolone plus rituximab; RIT: radioimmunotherapy; R/R: relapsed or refractory.]
Drug MOA (target) Eligibility
(and design)
Phase Randomized Results
I-131
tositumomab [96]
Anti-CD20
radioimmunotherapy
Previously
untreated DLBCL
(with R-CHOP)
No 1-year PFS rate: 75%; 1-year
OS rate: 83%
Inotuzumab
ozogamicin
(CMC-544) [93]
CD22 targeted
cytotoxic
immunoconjugate
R/R CD22+ and
CD20+ NHL (with
R)
IN o ORR: 80%; 1-year PFS rate:
89%
Inotuzumab
ozogamicin
(CMC-544) [94]
CD22 targeted
cytotoxic
immunoconjugate
R/R CD22+ and
CD20+ DLBCL
prior to
HDT-ASCT (with
R)
No ORR: 21%
90Y-epratuzumab
tetraxetan [92]
Radiolabeled
humanized
anti-CD22 mAb
R/R NHL I/II Dose-ﬁnding ORR: 62%; CR/CRu: 48%;
mPFS: 9.5 months
90Y-epratuzumab
tetraxetan [97]
Radiolabeled
humanized
anti-CD22 mAb
Consolidation after
ﬁrst-line R-CHOP
in DLBCL
II No Improved remission status
6weeks after RIT: 30.7%
Brentuximab
vedotin (SGN-35)
[104]
Antitubulin
monomethyl
auristatin E (MMAE)
anti-CD30 mAb
conjugate
R/R lymphoma I ORR: 46%; CR: 29%
events leading to discontinuation included neutropenia and
hyperbilirubinemia[95].Furtherstudiesofthiscombination
in NHL are ongoing (NCT00299494; NCT01232556).
90Y-epratuzumab-tetraxetan is a radiolabeled, human-
ized anti-CD22 antibody that has been used for fractionated
radioimmunotherapy (RIT) and has shown high rates of
durable CRs with manageable hematologic toxicity in pre-
viously treated patients with indolent and aggressive NHL
[96]. A phase II study, currently underway, is assessing 90Y-
epratuzumab-tetraxetan as consolidation therapy after ﬁrst-
line chemotherapy in disseminated DLBCL patients over 60
years of age [97]. 31% of patients in whom a CR, uncon-
ﬁrmed CR, or worse, was reported with R-CHOP improved
theirremissionstatus6weeksafterRIT.Thecommongrade3
or 4 toxicities reported were neutropenia (78%) and throm-
bocytopenia (74%). A phase I/II study of 90Y-epratuzumab-
tetraxetan combined with veltuzumab in patients with R/R
aggressive NHL is currently recruiting (NCT01101581).
Preclinical data indicate that the eﬃcacy of epratuzumab
conjugatedwithSN-38(theactivecomponentofthetopoiso-
merase I inhibitor, irinotecan) may potentially be enhanced
when combined with the CD20 immunotherapeutic, vel-
tuzumab [98].
90Y-ibritumomab tiuxetan (90Y-IT), an anti-CD20 mu-
rine antibody linked to a beta-emitting isotope, is appro-
ved for use in indolent lymphoma [99]. In a phase II
trial, 90Y-IT induction followed by rituximab maintenance
in patients with R/R DLBCL had an acceptable toxicity
proﬁle and the 2-week outpatient 90Y-IT infusion produced
response rates and durations similar to those of more pro-
longed cytotoxic chemotherapy regimens. Another phase II
trial showed 6 cycles of ﬂudarabine and mitoxantrone (FM)
followed by 90Y-IT in previously untreated, indolent, non-
follicular NHL to be tolerable and eﬀective, with a CR rate
of 50% after FM chemotherapy increasing to 100% at the
endofthetreatmentregimen[100].TheEasternCooperative
Oncology Group (ECOG) carried out a phase II study of R-
CHOPfollowedby 90Y-ITinpreviouslyuntreatedMCL.This
trial showed that failure-free survival appeared prolonged
over that expected with R-CHOP alone and the regimen was
considered to be safe, with neutropenia and thrombocytope-
nia being the most frequent adverse events [101].
Consolidative RIT with iodine-131 tositumomab was
administered in a phase II trial in 86 patients with previously
untreated DLBCL [102]. In this trial, 5 patients died of toxi-
cities possibly related to therapy, including 1 case of febrile
neutropenia, 1 case of acute myeloid leukemia (AML), and
one case of renal failure; 2 deaths were caused by cardiac
ischemia, 1 of which occurred after a gastrointestinal bleed
in a patient that became thrombocytopenic after iodine-131
tositumomab. The 1-year PFS and OS estimates were 75%
and 83%, respectively; given that the estimated historical 1-
year PFS rate with R-CHOP alone in this population is 74%,
a consolidation strategy utilizing iodine-131 tositumomab
after 8 cycles of CHOP (6 with rituximab) for DLBCL does
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OS. The authors concluded that in this population of
DLBCL, early progressions, deaths, and declining perfor-
mance status during CHOP limit the number of patients
who can ultimately beneﬁt from a planned consolidation ap-
proach. The use of novel agents earlier in therapy may have a
greater impact in DLBCL than consolidation or maintenance
approaches [102]. A phase II study of iodine-131 tositu-
momab for 1st- or 2nd-relapse indolent BCLs, or BCLs that
have transformed to a more aggressive histology, has been
completed recently (NCT00950755).
Thebindingproperties,internalizationkinetics,andclin-
icopathological activity of the ADC, brentuximab vedotin
(SGN-35),weredescribedrecently[103].Inaphase1,weekly
dosing study, brentuximab induced multiple objective res-
ponses in patients with R/R CD30-positive lymphomas
[104].DLTsincludeddiarrhea,vomiting,andhyperglycemia.
A novel ribonuclease-based immunotoxin comprising
quadruple ranpirnase (Rap) site speciﬁcally conjugated to an
anti-CD22 IgG has shown potent antilymphoma activity in
in vivo and in vitro assays [105].
4.AdditionalNovelStrategies
Adoptive transfer of autologous T-cells expressing anti-
CD19 chimeric antigen receptors (CARs) is a potential new
approach for treating B-cell malignancies [106]. A phase I
clinical trial of B-cell malignancies treated with autologous
anti-CD19-CAR-transduced T cells is ongoing, with data
published on ﬁve patients, having received two doses of
cyclophosphamide 60mg/kg and ﬁve doses of ﬂudarabine
25mg/m2 followedbyinfusionsofanti-CD19-CAR-transdu-
ced T cells and administration of high-dose interleukin-2
(IL-2). Initial results appear promising.
Therapeutic vaccination holds enormous potential as a
complementary treatment for NHL, and IL-2 has a wide
range of immunologic eﬀectsand is able to induce regression
of metastatic human tumors [107]. In a preclinical study, a
therapeuticvaccineusingtumorcellsactivatedbySalmonella
infection and IL-2 has been shown to induce antitumor
immunity in BCL.This approachmay havetherapeutic value
in promoting systemic immunity against human NHL.
To circumvent cytotoxic T-lymphocyte (CTL) tolerance
of tumor-associated antigens, noncognate cytotoxic T cells
have been retargeted against CD20+ tumor cells using [Fab’ x
MHCclassI/peptide] conjugates.Theability of[Fab’xMHC
class I/peptide] constructs to cause proliferation of OT-1
cells (a transgenic T-cell receptor model in which the CD8+
T-cells express a T-cell receptor speciﬁc for the SIINFEKL
peptide of ovalbumin) in vitro suggests that it may be pos-
sible to use a single molecule to generate a secondary cyto-
toxic T-cell response and, subsequently, to retarget it, thus
increasing the feasibility of the approach if adopted in the
clinical setting [108].
5.Other TargetedTherapies
5.1. Immunomodulating Agents (Table 4). Thalidomide and
its newer derivative, lenalidomide, have multifaceted anti-
tumor eﬀects that include immunomodulatory eﬀects via
natural-killer-cell recruitment and cytokine modulation,
antiangiogenesis, and the ability to alter tumor and stromal-
cell interactions [109]. An early study of thalidomide plus
rituximab found responses in 13/16 patients with relapsed
MCL, although follow-up was limited [110]. More recently,
data from 58 patients in a French compassionate-use study
provided good response data with limited toxicity [111].
LenalidomidemonotherapywasevaluatedinaphaseIIstudy
of 49 patients with R/R aggressive NHL, including 15 with
MCL [112, 113], and demonstrated an ORR of 35% with a
median duration of response (DR) of 6.2 months. Cytope-
nias, fatigue, constipation or diarrhea, rash, and fever were
common adverse events. A larger, international, conﬁrma-
tory phase II study in patients with R/R DLBCL or MCL
showed an ORR of 35%. Adverse events included grade 3 or
4 neutropenia (41%) and thrombocytopenia (19%) [114].
Pooled data of patients who had received prior SCT from
these 2 studies suggest lenalidomide to be eﬃcacious, with
a nO R Ro f3 9 % ,a n dw e l lt o l e r a t e d[ 115].
Preclinical evidence for synergistic activity of the lenali-
domide-rituximab combination in MCL [116, 117]i ss u p -
ported by results of a phase I/II study, which has shown a
53% ORR in patients with R/R MCL. Grade 3 or 4 toxicities
included neutropenia (37 events in 45 patients) [118]. The
evolving role of lenalidomide in relapsed MCL is further
strengthened by data from a phase II trial of lenalidomide
in combination with dexamethasone (ORR: 55%; grade 3 or
4 neutropenia in 48% of patients) [119], and with rituximab
and dexamethasone (ORR: 57%) [120]. Lenalidomide is also
being evaluated in combination with R-CHOP (R2-CHOP)
in a phase I/II trial in patients with aggressive BCLs [121]. A
second phase I study is ongoing [122]. Interim analysis of
a phase I/II trial of lenalidomide plus R-CHOP21 showed
multiple CRs and moderate hematologic toxicity (grade 3
or 4 neutropenia: 28%) [123]. Recruitment is ongoing for
a phase I/II study of lenalidomide, rituximab, and benda-
mustine in aggressive BCL (NCT00987493).
5.2. Proteosome Inhibitors (Table 5). B o rt e z o m i b ,ar e v e r s i b l e
inhibitor of the chymotrypsin-like activity of the 26S pro-
teasome, disrupts normal homeostatic mechanisms in cells
[124]. This agent is used widely to treat MM and is now
also approved for use in MCL. Its activity in combination
with other agents has been investigated in several recent
studies. R-CHOP plus bortezomib produced an ORR of
91%inpreviouslyuntreatedMCLpatients,withneutropenia
(23%) and thrombocytopenia (14%) among the grade 3
or 4 cytopenias that were reported [125]. A phase II study
of bortezomib in combination with bendamustine and
rituximab in patients with R/R indolent and MCL produced
an ORR of 84%, although the triple regimen appeared to
be more toxic than the bendamustine-rituximab regimen
alone [126]. Interim data from a phase II study suggested
promising results for a regimen of bortezomib plus dose-
dense CHOP every 2 weeks as ﬁrst-line treatment in
disseminated DLBCL [127]. A recent study by Dunleavy and
colleagues[128]showedthatalthoughbortezomibalonehad
no activity in DLBCL, when combined with chemotherapy
it demonstrated a signiﬁcantly higher response in ABC8 Advances in Hematology
Table 4: Immunomodulatory agents in clinical development for the treatment of aggressive NHL. [B: bortezomib; CR: complete response;
CRR: complete response rate; CRu: unconﬁrmed CR; Dex: dexamethasone; MCL: mantle cell lymphoma; mDR: median duration of
response; mEFS: median event-free survival; MOA: mechanism of action; mPFS: median progression-free survival; NHL: non-Hodgkin
lymphoma;ORR:overallresponserate;OS:overallsurvival;PR:partialresponse;R:rituximab;R-CHOP21:cyclophosphamide,doxorubicin,
vincristine, prednisolone plus rituximab, every 21 days; R/R: relapsed or refractory; TTF: time to treatment failure.]
Drug MOA (target) Eligibility Phase Randomized Results
Thalidomide [111] Immunomodulator
R/R MCL (alone,
with R, with B,
with RB, with
other agents)
NA No
ORR: 50%; CR: 20.7; 2-year
TTF rate: 10.9%; 2-year OS
rate: 49.6%
Lenalidomide [113] Immunomodulator R/R aggressive
NHL
II No
ORR: 35%; CR/CRu: 12%;
mDR: 6.2months; mPFS:
4.0months
Lenalidomide [114] Immunomodulator R/R aggressive
NHL
II No ORR: 35%; CR/CRu: 13%;
mPFS: 3.5months
Lenalidomide [116] Immunomodulator R/R MCL II No ORR: 53%; CR: 20%; mPFS:
5.6months
Lenalidomide [117] Immunomodulator R/R MCL (with
Dex)
II No ORR: 55%; CR: 24%
Lenalidomide [118] Immunomodulator R/R MCL (with R) I/II Dose-ﬁnding ORR: 53%; CRR: 31%; mPFS:
14.0months
Lenalidomide [120] Immunomodulator R/R Indolent or
MCL (with R/Dex)
II No ORR: 57%; mEFS: 12.0
months; 78%
Lenalidomide [121] Immunomodulator
Previously
untreated DLBCL
(with R-CHOP21)
I/II Dose-ﬁnding CR: 15/21; PR: 1/21
compared with GCB DLBCL. These results indicate that
bortezomib speciﬁcally beneﬁts non-GCB DLBCL patients,
who normally exhibit inferior outcomes relative to GCB
subtype patients after therapy with CHOP or R-CHOP. An
ongoing phase II study of R-CHOP with or without borte-
zomib is prospectively enrolling only those patients with the
non-GCB subtype DLBCL [129].
The combination of bortezomib and rituximab in a
weekly schedule has been shown to be eﬀective with little
hematologic toxicity in a phase II study in R/R indolent BCL
and MCL [130]. In another phase II study, a combination
of bortezomib plus rituximab, doxorubicin, dexamethasone,
and chlorambucil (RiPAD+C) was shown to be feasible and
well tolerated as a ﬁrst-line therapy in elderly MCL pa-
tients [131]. Bortezomib was used in place of vincristine in
the standard rituximab, cyclophosphamide, vincristine, and
prednisone (R-CVP) regimen in a phase I trial in R/R indo-
lent DLBCL and MCL [132]. The R-CBorP regimen appea-
red to be well tolerated and the eﬃcacy data looked promis-
ing.SeveralotherphaseIstudiesarefurtherexploringpoten-
tial uses of bortezomib, with positive data reported for its
use in combination with conatumumab [133], gemcitabine
[134], and 90Y-IT [135].
Numeroustrials thatareongoing or recruiting, areinves-
tigating the combination of bortezomib with rituximab-
ICE (RICE) (NCT01226849; NCT00515138), tositumomab
(NCT00398762), and vorinostat (NCT00837174). Preclini-
cal data support further combination regimens, including
romidepsin [136], autophagy inhibitors [137], the murine
double minute (MDM2) inhibitor, nutlin-3 [138], and the
BH3 mimetic, obatoclax [139].
NPI-0052 is a proteasome inhibitor with a novel bicyclic
structure [140]. In a phase I study, NPI-0052 produced dose-
dependent pharmacologic eﬀects, with less peripheral neu-
ropathy, neutropenia, and thrombocytopenia than was typi-
cally noted with other proteasome inhibitors. MLN9708 has
shownactivityinpreclinicalmodelsoflymphoma[141,142].
Further, the novel proteasome inhibitor carﬁlzomib has been
shown to interact synergistically with histone deacetylase
inhibitors (HDACIs) [143].
5.3. Phosphatidylinositol 3-Kinase (PI3K) Pathway (Table 5).
The PI3K-signaling pathway plays a major role in regulating
cellgrowthandsurvivalandisoftenderegulatedasaresultof
the mutation or ampliﬁcation of Akt [144, 145]. The mam-
malian target of rapamycin (mTOR) kinase is an essential
mediator of growth signaling that originates from PI3K.
mTOR activation by Akt leads to cell proliferation and sur-
vival by modulating critical molecules such as cyclin D1.
The rapamycin analogs, everolimus (RAD001) and tem-
sirolimus, are approved by the FDA for renal cell carcinoma
and have demonstrated activity against lymphoma cells both
in vitro and in vivo [146, 147]. Everolimus was evaluated
in a single-agent phase II study in patients with relapsed
aggressive NHL in whom standard therapy failed [148]. Sig-
niﬁcant responses were noted; grade 3 or 4 events included
anemia (14%), neutropenia (18%), and thrombocytopenia
(38%). In another single-agent phase II study, everolimus
showed moderate activity in patients with R/R MCL; grade
3 or 4 anemia and thrombocytopenia were reported in 11%
of patients [149]. A phase II study of the combination of
everolimus and rituximab in R/R DLBCL has just beenAdvances in Hematology 9
Table 5: Targeted therapies in clinical development for the treatment of aggressive NHL. [ABC: activated B-cell-like DLBCL; CR: complete
response;CRu:unconﬁrmedCR;DLBCL:diﬀuselargeB-celllymphoma;FL:follicularlymphoma;GCB:germinal-centerB-cell-likeDLBCL;
HDACI: histone deacetylase inhibitor; HL: Hodgkin lymphoma; Hsp: heat shock protein; mAB: monoclonal antibody; MCL: mantle cell
lymphoma; mDR: median duration of response; MOA: mechanism of action; mOS: median overall survival; mPFS: median progression-
free survival; mTOR: mammalian target of rapamycin; MZL: marginal zone B-cell lymphoma; NHL: non-Hodgkin lymphoma; ORR: overall
responserate;OS:overallsurvival;PI3K:phosphatidylinositol3-kinase;PFS:progression-freesurvival;PR:partialresponse;R:rituximab;R-
CHOP:cyclophosphamide,doxorubicin,vincristine,prednisoloneplusrituximab;R-ICE:rituximab,ifosfamide,carboplatin,andetoposide;
RiPAD+C: bortezomib plus rituximab, doxorubicin, dexamethasone, chlorambucil; R/R: relapsed or refractory; TLR: Toll-like receptor;
VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor.]
Drug MOA (target) Eligibility Phase Randomized Results
Bortezomib [127] Proteasome inhibitor
Previously
untreated DLBCL
(with R-CHOP)
I/II Dose-ﬁnding CR/CRu: 92%
Bortezomib [128] Proteasome inhibitor R/R DLBCL (with
chemotherapy) II No ABC versus GCB: ORR: 83% versus 13%;
mOS: 10.8 versus 3.4 months
Bortezomib [130] Proteasome inhibitor
R/R indolent
nonfollicular +
MCL (+R)
II No ORR: 53%; CR: 26.5%; PR: 26.5% 2-year
OS: 80%; 2-year PFS: 25%
Bortezomib [126] Proteasome inhibitor
R/R indolent +
MCL with
R/bendamustine
II No ORR: 84%; CR/CRu: 52%
Bortezomib [131] Proteasome inhibitor
Previously
untreated MCL
(RiPAD + C)
II No ORR: 80%; CR: 51% after 4 cycles
NPI-0052 [141] Proteasome inhibitor Multiple tumor
types I/II Dose-ﬁnding
Clinical beneﬁt observed in multiple
tumor types including MCL, HL, cuta-
neous MZL, and FL
Everolimus [150] mTOR inhibitor R/R MCL II No ORR: 12%
Everolimus [151] mTOR inhibitor R/R NHL II No ORR: 30%; mDR: 5.7 months
Everolimus [152] mTOR inhibitor R/R NHL I 2 dose cohorts 2 responses in DLBCL and 2 responses in
FL, in 13 patients
Everolimus [149] mTOR inhibitor R/R MCL II No ORR: 20%; mDR: 5.45 months
Temsirolimus [153] mTOR inhibitor
R/R MCL (2
doses, compared
with
investigators’
choice therapy)
III Yes
ORR: 22% (temsirolimus 175/75mg) ver-
sus 2% (investigators’ choice); mPFS: 4.8
months (temsirolimus 175/75mg) ver-
sus 3.4 months (temsirolimus 175/25mg)
versus 1.9months (investigators’ choice);
OS: 12.8 months (temsirolimus 175/
75mg) versus 9.7 months (investigator’s
choice)
Temsirolimus [154] mTOR inhibitor R/R MCL (with
rituximab) II No ORR: 59%; CR: 19%; PR: 40%
Vorinostat [167] Deacetylase inhibitor R/R lymphoma
(with R-ICE) IN o 19/27 responses
Vorinostat [168] Deacetylase inhibitor R/R lymphoma
(with DOXIL) I Dose-ﬁnding 4/14 disease control
Oblimersen sodium
[183]
Bcl-2 antisense
oligonucleotide
R/R B-cell NHL
(with R) II No ORR: 42%; ORR in FL: 60%
PF-3512676 [209] TLR9-antagonist R/R NHL (with
R) I Dose-ﬁnding ORR: 24%; ORR in extended treatment
cohort: 50%
17-AAG [216] HSP90 inhibitor R/R MCL or HL II No ORR: 11% (all PR)
Bevacizumab [221] Anti-VEGF mAb
Previously
untreated DLBCL
(with R-CHOP)
II No
1-year PFS rate: 77%; 2-year PFS rate:
69%; 1-year OS rate: 86%; 2-year OS rate:
79%
Aﬂibercept [220] VEGF fusion protein
Previously
untreated B-cell
lymphoma (with
R-CHOP)
I Dose-ﬁnding ORR: 100%; CR: 80%
CAL-101 [157] PI3K inhibitor R/R NHL IN o RR: relapsed MCL: 73%;
RR: refractory MCL: 40%
Valproic acid [171]H D A C I R / R N H L II No ORR: 29% (all PR)10 Advances in Hematology
completed(NCT00869999).Preliminaryresultsfromaphase
II study in MCL patients refractory to bortezomib reported
promising single-agent activity and good tolerability [150].
A Japanese phase I study in patients with R/R NHL has also
shownpreliminaryevidenceofactivityofeverolimusinNHL
[151]. Phase I/II studies exploring the novel combinations of
everolimusandpanobinostat(LBH589)[152]orbort ez omib
(NCT00671112) are ongoing.
A phase III study of R/R MCL comparing temsirolimus
with physician’s choice demonstrated an ORR of 22% and
2%, respectively [153]. A phase II study of temsirolimus plus
rituximab produced a 59% ORR; the most common grade
3 or 4 adverse event in rituximab-sensitive and -refractory
patients was thrombocytopenia (17% and 38%, resp.) [154].
Temsirolimus also shows some activity in DLBCL with an
ORR of 28%, a CR of 12%, and a median PFS of 2.6 months
[155].
The PI3K p110δ isoform is preferentially expressed in
cells of hematologic origin and in a variety of malignant cells
[156]. CAL-101 is a potent p110δ inhibitor and has shown
acceptable safety and promising pharmacodynamic and cli-
nical activity in a variety of hematologic malignancies, as a
single agent [157–159] and in combination with rituximab
or bendamustine [160].
SF1126 is a dual PI3K/mTOR inhibitor and is currently
in phase I development in B-cell malignancies [161]. Other
novel approaches under investigation in preclinical trials
include combining mTOR inhibitors with rapamycin-resis-
tant T cells [162], targeting the PI3K/Akt/survivin pathway
with the protease inhibitor, ritonavir [163], dual mTORC1/
mTORC2 inhibition [164], and use of immunosuppressive
agents (e.g., ﬁngolimod; FTY720) to downregulate cyclin D1
and pAkt [165].
5.4. DACs/HDACIs (Table 5). Several groups of HDACIs
have been developed, and they all show activity in lym-
phoma, mostly cutaneous [166]. HDACIs have been shown
topromoteapoptosisandtoreduceangiogenesis.Vorinostat,
registered for R/R cutaneous T-cell lymphoma (CTCL),
works synergistically with other drugs, but its role in the
treatment of DLBCL is not clear yet. A number of phase
I studies of vorinostat-combination regimens in relapsed
lymphoma are either ongoing or have been completed
recently. These studies have incorporated R-ICE/ICE [167],
pegylated liposomal doxorubicin [168], and conatumumab
[133]. Preclinical evidence supporting the clinical develop-
ment of vorinostat plus the novel Aurora kinase inhibitor,
MK-5108, has also been presented [169]. A recent safety and
tolerabilityanalysisofpriorphaseIandIItrialsofvorinostat-
based therapy in CTCL, other hematologic malignancies,
and solid tumors, highlighted fatigue (62%) and nausea
(56%) as the most common drug-associated adverse events,
with fatigue (12%) and thrombocytopenia (11%) the most
common grade 3 or 4 adverse events [170].
Valproic acid functions as a HDACI, although data on its
activity are limited [171]. A recent phase II trial in refractory
lymphoma produced 4/14 responses (all partial responses
(PRs)).AnearlierphaseIstudywithdecitabineshoweddose-
limiting myelosuppression and infectious complications
whichprecludeddoseescalationtoaminimumeﬀectivedose
[172].
Panobinostatisanoralpan-DACIthathasshownactivity
in a variety of cancers. Responses have been documented in a
phase II study in relapsed HL [173] and in combination with
everolimus in a phase I/II study in R/R HL and NHL [152]. It
isalsobeinginvestigatedinDLBCL,wherepreclinicalactivity
has been observed in combination with decitabine [174].
The HDACI, belinostat, has broad preclinical activity
[175]. Interim results from a phase I study in patients with
lymphoid malignancies provided evidence of tumor shrink-
age, and a phase II, Southwest Oncology Group (SWOG)
study in patients with R/R aggressive B-cell NHL is ongoing
(NCT00303953).
PCI-24781 is a broad-spectrum HDACI, which has
shown activity in lymphoma cell lines and models [176]. It
has also demonstrated safety and initial clinical beneﬁt in a
phase I study in R/R lymphoma.
Entinostat (SNDX-275) is an oral, class I isoform-selec-
tive HDACI [177]. A number of responses have been obser-
vedinanongoingphaseIIstudyinR/RNHL,andsynergistic
preclinical activity has been reported in combination with
bortezomib [178].
Preclinical activity has also been observed with panobi-
nostat [179, 180] and the oral heat-shock-protein- (Hsp-) 90
inhibitor, SNX-2112 (in combination with bortezomib and
rituximab) [181].
5.5. Cell Death (Bcl Family) (Table 5). The intrinsic cell-
death pathway is triggered at the mitochondria by a range
of signals, with the most important regulators residing in
the Bcl-2 family [182]. The Bcl-2 antisense nucleotide, obli-
mersen, was evaluated in a phase II study in combination
with rituximab in patients with recurrent B-cell NHL. An
ORR of 42% was found and most toxicity was low in grade
and was reversible [183].
ABT-263 (navitoclax) is currently being investigated in
clinical trials of lymphoma, as monotherapy [184] and in
combination with rituximab [185]. The experimental Bcl-2
inhibitor, ABT-737, is in preclinical development for MCL
[186]a n dD L B C L[ 67]. Other agents in preclinical develop-
ment include obatoclax (in combination with bortezomib)
[140, 187] and YM155 [188, 189].
5.6. Kinase Inhibitors (Table 6). Aurora kinases A and B
(AAK and ABK) are oncogenic serine/threonine (S/T) kina-
ses that play central roles in the mitotic phase of the euka-
ryotic cell cycle [190]. Overexpression of Aurora kinases
during the cell cycle can override mitotic and spindle check-
points leading to aneuploidy in many human cancers. Gene
expression proﬁling in aggressive B- and T-cell NHL has
showntheAurorakinasestobeoverexpressedsuggestingthat
they may be key component genes of the “proliferative” sig-
nature.
MLN8237 is a selective AAK inhibitor, which showed
synergy with docetaxel in preclinical models of MCL [191].
In a phase I study in patients with advanced hematologic
malignancies, durable responses were observed, with neu-
tropenia (46%) and thrombocytopenia (36%) being theAdvances in Hematology 11
Table 6: Kinase inhibitors currently in clinical development for the treatment of aggressive NHL. [CDK: cyclin-dependant kinase; CLL:
chronic lymphocytic leukemia; CR: complete response; DLBCL: diﬀuse large B-cell lymphoma; ERK: extracellular signal regulated kinase;
FFP: freedom from progression; FL: follicular lymphoma; HL: Hodgkin lymphoma; JAK: Janus kinase; MCL: mantle cell lymphoma; mPFS:
median progression-free survival; NHL: non-Hodgkin lymphoma; MEK: mitogen-activated protein kinase kinase; MM: multiple myeloma;
mTOR: mammalian target of rapamycin; ORR: overall response rate; OS: overall survival; PDGF: platelet-derived growth factor; PDGFR:
platelet-derived growth factor receptor; PFS: progression-free survival; PR: partial response; R/R: relapsed or refractory; RTK: receptor
tyrosine kinase; SD: stable disease; SLL: small lymphocytic lymphoma; TKI: tyrosine kinase inhibitor; VEGFR: vascular endothelial growth
factor receptor.]
Drug MOA (target) Eligibility Phase Randomized Results
Dinaciclib [183] C D K 1 ,2 ,5 ,9
inhibitor
R/R in low-grade
lymphoma and
DLBCL
IN o P R :D L B C L :1 / 7 ;S D :F L :2 / 7 ;
MCL: 1/1
Fostamatinib [198] Syk inhibitor R/R B-cell NHL
and CLL
I/II No
ORR: DLBCL: 22%; FL: 10%
SLL/CLL:55%inSLL/CLL:MCL:
11%; overall mPFS: 4.2 months
Dasatinib [202]
RTK inhibitor of
BCR-ABL, SRC,
c-Kit, PDGF and
ephrin receptor
kinases
R/R NHL I/II No ORR: 32%; 2-year PFS: 13%; 2-
year OS: 50%
Enzastaurin [201] Protein kinase beta
inhibitor R/R DLBCL II No FFP: 22%
PCI-32765 [204] Bruton’s tyrosine
kinase inhibitor R/R B-cell NHL I Dose-ﬁnding ORR: 43%
SB1518 [208] JAK2 inhibitor R/R lymphoma I Dose-ﬁnding PR: 3/26 (2 in MCL)
Sorafenib [221]
TKI inhibitor of
RAF/MEK/ERK/c-
kit/Flt3, VEGFRs,
PDGFRs, RET
R/R NHL II No ORR: 10%; CR: 5%
Sorafenib [222]
TKI inhibitor of
RAF/MEK/ERK/c-
kit/Flt3, VEGFRs,
PDGFRs, RET
R/R lymphoma
(with Akt inhibitor
perifosine)
II No ORR: 23% (all PR; all in HL)
Sorafenib [223]
TKI inhibitor of
RAF/MEK/ERK/c-
kit/Flt3, VEGFRs,
PDGFRs, RET
R/R MM or
lymphoma (with
mTOR inhibitor
everolimus)
I/II Dose-ﬁnding ORR: 33%
most common treatment-related adverse events [192]. A
subsequent phase II study in patients with aggressive NHL
is ongoing (NCT00807495).
The selective ABK inhibitor, AZD1152, potently inhib-
ited a range of tumor xenografts in immunodeﬁcient mice
[193] and is currently in phase I/II development for DLBCL
(NCT01354392). Aurora kinases in preclinical development
includethenovelpan-Aurora/JAK-2kinaseinhibitorAT9283
[194].
A number of cyclin modulators are currently in devel-
opment, including the cyclin-dependant kinase (CDK) inhi-
bitors ﬂavopiridol, which is in a phase I/II study in relap-
sed MCL/DLBCL (NCT00445341), and dinaciclib (SCH
727965), which has shown clinical responses in a phase I
studyinheavilypretreateddiﬀuselargecelllymphoma[195].
A phase I dose-escalation study of the cyclin D modulator
ON 013105 in patients with R/R lymphoma is ongoing
(NCT01049113) after showing promising in vitro and in vivo
data in MCL [196].
Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor
which has shown synergistic activity with a number of agents
in in vivo models of DLBCL [197]. In a recent phase I/II
study in NHL and CLL, substantial responses were observed
in a number of tumor types. Common toxicities included
diarrhea, fatigue, cytopenias, and hypertension [198].
Activation of protein kinase C (PKC) and its overexpres-
sion have been associated with a less favorable outcome in
DLBCL [199]. Enzastaurin is an inhibitor of PKC-β [200].
In a phase II study in R/R DLBCL, prolonged freedom from
progression (FFP) was observed with little grade 3 toxicity.
Preliminary results from a subsequent study in aggressive
NHL also indicate single-agent activity [201]. A phase III
study with daily enzastaurin to prevent relapse in DLBCL
patients in remission after R-CHOP treatment is currently
ongoing (NCT00332202).
Dasatinib has shown single-agent activity in a phase I/II
study in R/R NHL [202]. Pleural eﬀusions and cytopenias
were the main grade 3 or 4 toxicities. A phase II study in R/R
DLBCL (NCT00918463) is currently recruiting.12 Advances in Hematology
Bruton’s tyrosine kinase (Btk) is a mediator of B-cell sig-
naling, and PCI-32765 is a selective, irreversible inhibitor
of Btk [203]. In a phase I study in patients with R/R B-cell
malignancies, PCI-32765 induced durable responses with
minimal toxicity [204]. Encouraging initial clinical results
with the anaplastic lymphoma kinase (ALK) inhibitor crizo-
tinib in advanced chemoresistant ALK+ lymphoma patients
have also been observed [205].
The benzimidazole AZD6244 (ARRY-142886) is a novel,
2nd-generation mitogen-activated protein kinase (MEK) in-
hibitor [206]. Considerable cell death was shown in DLBCL
cell lines, primary cells, and in an in vivo xenograft model, at
clinically achievable concentrations.
5.7. JAK/STAT Pathway. The Janus kinase 2 (JAK-2)/signal
transducers and activators of transcription (STAT) pathway
playakeyroleintheproliferationandpathogenesisofhema-
tologic malignancies [207]. A phase I study of the novel
JAK-2 inhibitor, SB1518, has provided evidence of activity in
patients with relapsed lymphoma. Degrasyn, a novel, small-
molecule inhibitor of the JAK/STAT pathway, has been
shown to interact synergistically with bortezomib in vivo to
prevent tumor development and to prolong survival time in
a xenotransplant severe combined immunodeﬁcient (SCID)
mouse model of MCL [208].
5.8. Toll-Like Receptor (TLR) Agonist (Table 5). PF-3512676
is a novel TLR9-activating oligonucleotide with single-agent
antitumor activity that augments preclinical rituximab eﬃ-
cacy [209]. Preliminary antitumor activity for the combina-
tion was found by a phase I study in patients with recurrent,
indolent,andaggressiveNHL,whilegrade3or4neutropenia
occurred in 4/50 patients.
Evaluation of a combination regimen involving a TLR7/8
dual agonist (IMO-4200) with rituximab, bortezomib, or
cyclophosphamide, in human xenograft and murine syn-
geneic lymphoma models suggests that the antitumor activ-
ity of these agents in the treatment of NHL and other hema-
tologic malignancies could be enhanced using this strategy
[210]. The transforming-growth-factor- (TGF-) β-activated
kinase 1 (TAK-1) inhibitor, AZ-Tak1, has been shown to
inhibit X-linked inhibitor of apoptosis protein (XIAP), acti-
vate caspase-9, and induce apoptosis in MCL cell lines [211].
Immunostimulatory CpG oligodeoxynucleotides (OD-
Ns) are potent activators of T-cell immunity and antibody-
dependentcellularcytotoxicity(ADCC)andareunderinves-
tigation as immunotherapeutic agents for a variety of malig-
nancies, including BCL [212]. Anti-CD20 antibody-CpG
conjugates have been shown to eradicate rituximab-resistant
BCL in a syngeneic murine lymphoma model. A recent de-
monstration of the divergent eﬀects of CpG ODNs on nor-
mal versus malignant B cells may suggest a novel mechanism
ofactionforCpGODNsastherapeuticagentsforBCL[213].
5.9. Heat Shock Proteins (Hsps) (Table 5). Hsps are chaper-
ones needed for the correct functioning of proteins involved
in cellgrowth and survival[214].Inhibition of these proteins
results in increased degradation of key proteins such as
kinases, signal transducer proteins, and mutated oncogenic
proteins. GUT-70, a tricyclic coumarin derived from Calo-
phyllum brasiliense, has shown pronounced antiproliferative
eﬀectsinMCLwithmutant-typep53(mt-p53),aknownneg-
ative prognostic factor for MCL, through Hsp90 inhibition.
These ﬁndings suggest that GUT-70 could be potentially
useful for the treatment of MCL [215].
The small-molecule 17-AAG (17-allylamino-17-demeth-
oxygeldanamycin) can induce cell death in a dose- and time-
dependent manner by reducing the cellular contents of criti-
cal survival proteins, including Akt and cyclin D1 in a range
of lymphoma cell lines [216]. Several clinical responses were
observed in a phase II study of 17-AAG in patients with
R/R MCL or HL. SNX-2112 was found to exert eﬀects in
combination with bortezomib and rituximab in rituximab-
resistantNHLcelllines[181].SNX-2112iscurrentlyinphase
I clinical trials.
5.10. Angiogenesis (Table 5). Tumor angiogenesis is impor-
tant in a variety of hematologic malignancies [217]. Beva-
cizumab, already widely studied in solid tumors, has also
beenevaluatedinlymphoma.InaphaseIISWOGstudyofR-
CHOP plus bevacizumab in patients with advanced DLBCL,
the observed 1-year PFS estimate trended higher than the
historical estimate. However, as signiﬁcant toxicities were
associatedwiththeadditionofbevacizumabtheregimenwas
not recommended for further evaluation [218]. In a phase II
studyofsingle-agentsunitinibinR/RDLBCL,noevidenceof
activity was recorded and hematologic toxicities were greater
than anticipated [219]. The vascular-endothelial-growth-
factor- (VEGF-) 1/2 fusion protein, aﬂibercept, has been
evaluated in a phase I study in combination with R-CHOP
in untreated patients with BCLs [220]. The 6mg/kg dose
of aﬂibercept is used in all ongoing phase III trials in other
indications, and the combination with R-CHOP resulted in
high response rates in this study. The main grade 3 or 4
adverse events included hypertension (8/25), febrile neu-
tropenia (4/25), and asthenia (4/25).
Preliminary results are available from 2 recent phase II
trials with sorafenib. In a single-agent study in heavily pre-
treated patients with R/R NHL, a number of responses were
notedandtherapywasoverallwelltolerated[221].Inaphase
II study in combination with the Akt inhibitor perifosine
in R/R lymphomas, a number of PRs were observed, with
thrombocytopenia (18%) the most common drug-related
hematological toxicity [222]. A phase II study in recurrent
DLBCL is currently ongoing (NCT00131937). The combina-
tion of sorafenib and everolimus was shown to be well
tolerated, with activity observed, especially in HL, in a phase
I trial in patients with lymphoma or MM [223].
5.11. Additional Targeted Agents and Novel Therapeutics.
Farnesyltransferases are key cellular enzymes involved in the
prenylation of proteins [224]. Prenylated proteins are impor-
tant for malignant cell growth. The oral farnesyltransferase
inhibitor, tipifarnib, has been assessed in a phase II study in
patients with relapsed, aggressive, indolent, or uncommon
lymphoma. Tipifarnib had a good tolerability proﬁle and
demonstrated activity in lymphoma, with responses inAdvances in Hematology 13
Table 7: Overview of ongoing or recently completed phase III studies mentioned in this paper, with agents in clinical development for the
treatment of aggressive NHL. [B: bendamustine; CR: complete response; DLBCL: diﬀuse large B-cell lymphoma; F: ﬂudarabine; MCL:
mantle cell lymphoma; NA: not applicable; NHL: non-Hodgkin lymphoma; PFS: progression-free survival; R-CHOP: cyclophosphamide,
doxorubicin, vincristine, prednisolone plus rituximab; R: rituximab; R/R: relapsed or refractory; SCT: stem cell transplantation.]
Drug Indication Study identiﬁer Study status Results
Enzastaurin
DLBCL in remission
after R-CHOP
treatment
NCT00332202 PRELUDE Ongoing; not
recruiting NA
Inotuzumab ozogamicin
+Rv e r s u si n v e s t i g a t o r ’ s
choice of gemcitabine +
Ro rB+R
R/R aggressive NHL NCT01232556 Recruiting NA
B+Rv e r s u sF+R[ 41] R/R follicular,
indolent, and MCL NCT01456351
Completed; ﬁnal
results presented at
ASH 10
B+Rh a db e t t e r
eﬃcacy than F + R
B+Rv e r s u sR - C H O P
[42]
Previously untreated
follicular, indolent,
and MCL
NCT00991211
Completed; ﬁnal
results presented at
ASH 09
B + R superior to
R-CHOP for CR and
PFS
Single-agent pixantrone
dimaleate versus
investigator’s choice
therapy [49]
Third-line treatment
of R/R aggressive
NHL
NCT00088530 EXTEND
(PIX301)
Completed; ﬁnal
results presented at
ASH 10
Pixantrone superior
to other single-agent
therapies
Pixantrone + R versus
gemcitabine + R
R/R DLBCL patients
not eligible for SCT
NCT01321541 PIX-R
(PIX306) Recruiting NA
patients with heavily pretreated DLBCL, HL, and T-cell
types, although little activity was observed in follicular NHL.
MLN4924 is an investigational inhibitor of Nedd8-acti-
vating enzyme (NAE), which plays a crucial role in regu-
latingtheactivityofthecullin-RINGE3ligases(CRLs)[225].
Preclinicalactivityhasbeendemonstratedinanovelprimary
human DLBCL xenograft model [226] and a phase 1 dose-
escalation study of multiple dosing schedules is currently
underway in patients with R/R MM or lymphoma [225].
Potential molecular targets for novel therapeutics (or
“theranostics”) are beginning to be identiﬁed through an
emerging area in lymphoma biology involving energy meta-
bolism. Personalized medicine approaches using bifunc-
tional imaging and therapeutic agents are based on the pre-
mise that glucose metabolism rates are high in aggressive B-
cell lymphomas [227]. Use of this bifunctional pathway as a
targetedtherapyhasbeenexploredrecentlywith 187rhenium-
ethylenedicysteine-N-acetylglucosamine, a synthetic glucose
analog, which accumulates in cancer cell nuclei and in
varioustumorsinanimalmodels.Biodistributiondatarevea-
led that radioactivity was retained in tumor tissue 2 hours
after injection with little uptake in the plasma when com-
pared with tumor tissue. The compound was excreted over
a longer incubation period, and the retention time in lym-
phoma tissue was longer than that of other tissues. The
results suggest that the metallic pharmaceutical agent 187Re-
ECG may be a potential candidate for targeted therapy in
aggressive R/R lymphomas.
The recently developed, small-molecule MDM2 antago-
nist, nutlin-3, inhibits the MDM2-p53 interaction, resulting
in stimulation of p53 activity and apoptosis [228]. The cyto-
toxic eﬀects of nutlin-3 on ALL cells suggest that the agent
may be a novel therapeutic for refractory ALL [138, 228].
Stromal-cell-derived-factor-1 (SDF-1) is a chemokine
that binds to the CXCR4 chemokine receptor and stimulates
B-cell growth [229]. CXCR4 is frequently overexpressed on
tumor cells, and the SDF-1/CXCR4 axis is thought to play
a role in promoting survival, angiogenesis, and metastasis.
Treatment with the CXCR4 antagonist, AMD3100, has been
shown to enhance antibody-mediated cell death in dissem-
inated lymphoma models, suggesting a potential role for
CXCR4 antagonists in combination with a B-cell targeted
therapy in the treatment of B-cellmalignancies in the clinical
setting.
MCL is characterized by the translocation t(11; 14)(q13;
q32) [230]. All-trans retinoic acid (ATRA) is a key retinoid
that acts through nuclear receptors that function as ligand-
inducible transcription factors [231]. MCL cells express
retinoid receptors; therefore ATRA may exert antiprolifer-
ative eﬀects and, thus, may have a role in treatment. In a
recent study, a novel approach to deliver ATRA to MCL cells
in culture involved stably incorporating the water-insoluble
bioactive lipid into nanoscale lipid particles, termed nan-
odisks (ND), comprised of disk-shaped phospholipid bilay-
ers stabilized by amphipathic apolipoproteins. ATRA-ND
wasshowntoenhanceapoptosis andcell-cyclearrestin MCL14 Advances in Hematology
cell lines, resulting in increased p21, p27, and p53 expression
and decreased cyclin D1 expression; these results suggest that
ATRA-ND may represent a potentially eﬀective approach to
the treatment of MCL.
Hypoxia-inducible-factor-1 (HIF-1) is a transcription
factor that serves as a master regulator of cellular responses
to hypoxia and regulates genes required for adaptation to
hypoxic conditions [232]. HIF-1a is commonly activated in
cancer cells, including under normoxic circumstances, by
oncogene products or by impaired activity of tumor sup-
pressor genes. PX-478, the novel, small-molecule HIF-1a
inhibitor, has been shown to downregulate HIF-1a protein
at low concentrations eﬀectively and to induce cell death in
DLBCL cells.
6. Conclusion
Inadditiontothenumerouscytotoxiccombinationregimens
already available, a myriad of new agents are in development,
targeting key molecular pathways critical to aggressive B-cell
growth (Table 7). As monotherapy, or in combination with
chemotherapy or other targeted agents, these new pharma-
cotherapies are likely to provide additional clinical beneﬁt to
patients with aggressive B-cell NHL and represent continued
progress in the search for individualized treatments. As indi-
vidualized therapy will depend on the identiﬁcation of pre-
dictive markers, future clinical trials should incorporate the
identiﬁcation of molecular markers in their “smart” trial
design. How the search for individualized treatment will
aﬀect drug development and improve clinical trial design
remains to be seen.
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